Your Health, We Care
Multiple international treatment guidelines, including the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO), have listed Capmatinib as the first-line treatment of METex14 skipping NSCLC.
In the 2024 CSCO guidelines for the diagnosis and treatment of non-small cell lung cancer, Capmatinib is also recommended for first-line treatment of MET ex14 jumping mutation non-small cell lung cancer.
Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells by inhibiting MET phosphorylation triggered by hepatocyte growth factor binding or MET amplificatio···【more】
Article source：Lucius LaosRelease date：2024-08-07Recommended：93
Capmatinib is highly selective for c-Met targets, can effectively inhibit the proliferation and migration of c-Met-dependent tumor cells, and can effectively induce apoptosis to ac···【more】
Article source：Lucius LaosRelease date：2024-08-07Recommended：121
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or triggered by MET amplification, as well as MET-mediated phosphorylation of downstream signaling prote···【more】
Article source：Lucius LaosRelease date：2024-08-06Recommended：98
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
